Date: 2017-09-25
Type of information: Grant
Company: eTheRNA immunotherapies (Belgium)
Investors: Flanders Innovation & Entrepreneurship (VLAIO) (Belgium)
Amount: €1 million
Funding type: grant
Planned used:
- The grant will be used by eTheRNA to further develop and optimize its state-of-the-art production process for generating the mRNA components of its TriMix platform, and for clinical trials of innovative and rationally designed mRNA cancer immunotherapies derived from this platform. The improved production process will enable the company to further reduce its production time and cost of goods and generate more revenues from the production of GMP-grade mRNA for third parties.
- The TriMix platform combines three mRNAs encoding proteins that act highly synergistically to activate dendritic cells to promote enhanced T-cell immunity. In combination with mRNA coding for tumor-specific antigens, TriMix products can also promote an antigen-directed cytotoxic T-cell response.
Others:
- • On September 25, 2017, eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its TriMix platform, announced it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO).
Therapeutic area: Cancer - Oncology
Is general: Yes
